Table 3.

Cox regression of outcomes by drug treatment group within BMI groups ^*

	BMI<25				25≤BMI<30				BMI≥30
	CCB vs Diuretic		ACE-I vs Diuretic		CCB vs Diuretic		ACE-I vs Diuretic		CCB vs Diuretic		ACE-I vs Diuretic
	HR	p	HR	p	HR	p	HR	p	HR	P	HR	p
CHD†	1·04	0·669	1·19	0·058	1·04	0·568	1·00	0·971	0·91	0·192	0·85	0·024
CCHD	1·02	0·840	1·11	0·176	1·04	0·430	1·08	0·145	0·96	0·463	0·96	0·468
CCVD	1·07	0·264	1·07	0·228	1·02	0·606	1·13	0·002	1·03	0·417	1·06	0·124
HF	1·34	0·012	1·17	0·189	1·23	0·019	1·28	0·005	1·48	0·00	1·17	0·052
Hosp/Fatal HF	1·31	0·032	1·11	0·413	1·20	0.056	1·19	0·071	1·46	0·000	1·05	0·606
Stroke	0·97	0·792	1·14	0·311	0·89	0·256	1·15	0·162	0·95	0·642	1·15	0·141
Death	1·00	0·969	1·01	0·845	0·98	0·661	1·01	0·918	0·90	0·088	0·97	0·633
ESRD‡	0·64	0·110	0·98	0·936	1·00	0·983	0·86	0·444	1·49	0·020	1·49	0·022
Cancer	1·13	0·237	1·05	0·663	1·00	0·980	1·06	0·427	0·97	0·707	0·93	0·329
Hosp/Treated Angina	0·97	0·728	1·04	0·710	1·01	0·931	1·16	0·019	1·05	0·414	1·09	0·175
Hosp Angina	0·90	0·395	1·10	0·419	1·01	0·946	1·17	0·040	0·99	0·888	1·02	0·798
CRVSC	1·15	0·233	1·16	0·207	1·13	0·095	1·12	0·125	1·04	0·611	1·04	0·578
PAD	1·02	0·867	0·92	0·580	0·81	0·093	1·17	0·163	0·81	0·114	0·95	0·705

Abbreviations: ACE-I, angiotensin-converting-enzyme inhibitor; BMI, body mass index; CCB, calcium channel blocker; CCHD, combined coronary heart disease; CCVD, combined cardiovascular disease; CHD, coronary heart disease; CRVSC, coronary revascularization; ESRD, end stage renal disease; HF, heart failure; Hosp., hospital; PAD, peripheral artery disease

^*The following independent variables were used in the Cox regression: age, male gender, black race, diabetes history, current smoker.

^†Significant interaction between CHD and BMI for ACEI vs. Diuretic when interaction term included in the Cox regression (p=0·004).

^‡Significant interaction between ESRD and BMI for CCB vs. Diuretic when interaction term included in the Cox regression (p=0·011)